Home › Trials › NCT06854952

Evaluating TERN-601 for treating overweight and obesity in adults

A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

PHASE2 · Terns, Inc. · NCT06854952

This study is testing a new pill called TERN-601 to see if it can help adults who are overweight or obese lose weight safely and comfortably.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment150 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorTerns, Inc. (industry)
Locations17 sites (Birmingham, Alabama and 16 other locations)
Trial IDNCT06854952 on ClinicalTrials.gov

What this trial studies

This Phase 2a clinical trial is a multicenter, randomized, double-blind, placebo-controlled study aimed at assessing the efficacy, safety, and tolerability of TERN-601, an orally administered medication, in adults with overweight or obesity. Participants will be randomly assigned to receive either TERN-601 or a matching placebo. The study will focus on individuals with specific body mass index (BMI) criteria and will monitor their health outcomes over the course of the trial.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 to 75 with a BMI between 27 and 50 kg/m², particularly those with weight-related comorbidities.

Not a fit: Patients with diabetes mellitus, those whose obesity is induced by medication or other endocrine disorders, or individuals with a history of suicide attempts may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new oral option for managing overweight and obesity, potentially improving health outcomes for patients.

How similar studies have performed: Other studies involving GLP-1 receptor agonists have shown promise in treating obesity, suggesting that this approach may be effective.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

1. Female or male aged 18 to 75 years
2. Body mass index (BMI) of:

   1. ≥ 30 kg/m\^2 to \< 50 kg/m\^2

      OR
   2. ≥ 27 kg/m\^2 to \< 30 kg/m\^2 with at least 1 weight-related comorbidity
3. HbA1c \< 6.5%
4. Stable self-reported body weight for at least 3 months prior to study (\< 5% body weight gain or loss)

Key Exclusion Criteria:

1. Have diabetes mellitus
2. Have obesity induced by medication or other diagnosed endocrinologic disorders
3. Have had or are planning surgical treatment or device-based therapy for obesity
4. Lifetime history of suicide attempt

Where this trial is running

Birmingham, Alabama and 16 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Overweight or Obesity, overweight, obesity, obese, glucagon-like peptide-1 receptor agonist, GLP-1 receptor agonist, GLP-1

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.